CT-707, a novel FAK inhibitor, synergizes with Cabozantinib to suppress hepatocellular carcinoma by blocking Cabozantinib-induced FAK activation

Wang, D.-D.; Chen, Y.; Chen, Z.-b.; Yan, F.-J.; Dai, X.-Y.; Ying, M.-d.; Cao, J.; Ma, J.; Luo, P.; Han, Y.-X.; Peng, Y.; Sun, Y.; Zhang, H.; He, Q.-j.; Yang, B.; Zhu, H.

期刊名称Molecular Cancer Therapeutics
作者Wang, D.-D.; Chen, Y.; Chen, Z.-b.; Yan, F.-J.; Dai, X.-Y.; Ying, M.-d.; Cao, J.; Ma, J.; Luo, P.; Han, Y.-X.; Peng, Y.; Sun, Y.; Zhang, H.; He, Q.-j.; Yang, B.; Zhu, H.
印刷ISSN1535-7163
电子ISSN1538-8514
文件大小7614.61KB
发表时间2016-09-16
DOI10.1158/1535-7163.MCT-16-0282

发现好书期刊，享受阅读乐趣

CT-707, a novel FAK inhibitor, synergizes with Cabozantinib to suppress hepatocellular carcinoma by blocking Cabozantinib-induced FAK activation